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Abstract
Background: GLUT10 (gene symbol SLC2A10) is a facilitative glucose transporter within the type
2 diabetes (T2DM)-linked region on chromosome 20q12-13.1. Therefore, we evaluated GLUT10
as a positional candidate gene for T2DM in Caucasian Americans.
Methods: Twenty SNPs including 4 coding, 10 intronic and 6 5' and 3' to the coding sequence were
genotyped across a 100 kb region containing the SLC2A10 gene in DNAs from 300 T2DM cases
and 310 controls using the Sequenom MassArray Genotyping System. Allelic association was
evaluated, and linkage disequilibrium (LD) and haplotype structure of SLC2A10 were also
determined to assess whether any specific haplotypes were associated with T2DM.
Results: Of these variants, fifteen had heterozygosities greater than 0.80 and were analyzed
further for association with T2DM. No evidence of significant association was observed for any
variant with T2DM (all P ≥ 0.05), including Ala206Thr (rs2235491) which was previously reported
to be associated with fasting insulin. Linkage disequilibrium analysis suggests that the SLC2A10 gene
is contained in a single haplotype block of 14 kb. Haplotype association analysis with T2DM did not
reveal any significant differences between haplotype frequencies in T2DM cases and controls.
Conclusion: From our findings, we can conclude that sequence variants in or near GLUT10 are
unlikely to contribute significantly to T2DM in Caucasian Americans.
Background
Multiple genetic studies have been carried out that link
human chromosome 20q13.1-13.2 to type 2 diabetes
(T2DM) [1-5]. This linkage evidence has led investigators
to search for T2DM susceptibility genes in this genomic
region. Our laboratory has carried out analysis of specific
genes [6-8] and developed high resolution physical maps
of the region [9-11]. In an association analysis of genetic
markers Price et al. [12] identified three regions of T2DM
susceptibility. Among the genes mapped to the linkage
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disequilibrium regions, a novel facilitative glucose trans-
porter (GLUT) was identified and designated GLUT10
(gene symbol SLC2A10) [6,13]. The gene spans 28 kb of
genomic sequence, is split into 5 exons and 4 introns
[6,13] and is expressed mainly in heart, liver, lung, skele-
tal muscle, pancreas, placenta, thyroid, and adipose tissue
[6,13,14]. In Xenopus oocytes, human GLUT10 exhibited
a high affinity, saturable 2-deoxy-D-glucose transport
activity [6].
Glucose transport plays a central role in metabolism.
Defects in glucose transport have been implicated in the
reduced insulin sensitivity and in the increased insulin
resistance observed in type 2 diabetes [14,15]. The genes
coding for the classical GLUT1-5 proteins have been
extensively analyzed for mutations contributing to type 2
diabetes, but no common causative mutation has been
identified [16,17]. Both the function and genomic loca-
tion of the novel SLC2A10 gene are consistent with a role
in T2DM. In addition, Andersen et al. recently observed
evidence for association of an Ala206Thr polymorphism
in SLC2A10 with lower fasting insulin levels although
they observed no evidence for association with T2DM
[18]. We have carried out a systematic genetic evaluation
of SLC2A10 to assess association with T2DM.
Methods
Subjects
The individual samples evaluated in this study consisted
of a collection of 300 unrelated Caucasian T2DM patients
with end-stage renal disease (ESRD), with a correspond-
ing collection of 310 randomly-ascertained unrelated
Caucasian subjects without known diabetes. Both cases
and controls were recruited simultaneously. This group
will be referred to as "T2DM-ESRD"; their ascertainment
and recruitment have been previously described in detail
[19]. The T2DM-ESRD subjects have a mean age at diag-
nosis of diabetes of 46.5 ± 12.8 years, mean BMI at recruit-
ment of 28.5 ± 7.0, and mean maximum reported BMI of
36.1 ± 8.3, mean duration of diabetes > 15 years, and
mean HbA1c of 8.6%.
SNP selection and genotyping
Twenty SNPs used in this study were selected from the
dbSNP public database (rs1004571, rs6012006,
rs4810542, rs4810544, rs2425897, rs4428069,
rs2425902, rs6094438, rs2235491, rs2076293,
rs2425906, rs2425907, rs6094440, rs998422, rs2425911,
rs3091904, rs6018008, rs707507, rs1059217,
rs6090547). SNPs with frequency information were pref-
erentially selected. The majority of the SNPs had minor
allele frequencies greater than 0.2.
Genotyping was performed on a Sequenom MassArray
Genotyping System using methods previously described
Genomic map of the SLC2A10 gene with the locations of the  20 genotyped SNPs Figure 1
Genomic map of the SLC2A10 gene with the locations of the 
20 genotyped SNPs. The shaded regions are exons, num-
bered 1–5. The ruler along the bottom represents the rela-
tive location and spacing of SNPs in kilobases within the 40 
kb region containing SLC2A10. Note that this does not have 
a uniform scale.BMC Medical Genetics 2005, 6:42 http://www.biomedcentral.com/1471-2350/6/42
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[19]. Discordance between blind duplicate samples
included in the genotyping was <0.9% and the call rate for
each assay was set at ≥ 90%. Average call rate was 98.1%
(range 95.6% to 100%).
Statistical analysis
Pearson's test of homogeneity of proportions was applied
to analyze allele frequency differences between diabetic
and nondiabetic subjects SNPs were tested for Hardy-
Weinberg equilibrium and pairwise linkage disequilib-
rium statistics D' calculated using the SNP-Analysis soft-
ware package [20].
HAPLO.SCORE [21] was used to test for association of
haplotypes within the case-control populations.
HAPLO.SCORE uses posterior population-based fre-
quency weighting of haplogenotypes that have prior con-
sistency with observed heterozygous diplotypes. Variance
estimates are inflated to account for uncertainty in specific
haplotype assignment. We performed a global test of asso-
ciation between GLUT10 haplotypes and T2DM status,
followed by individual tests of haplotype risk, in a col-
lapsed 2 × 2 analysis. The skip.haplo option was set to
0.01. DANDELION [22], another expectation-maximiza-
tion (EM) algorithm-based program for haplotype analy-
ses was used to calculate haplotype frequencies in specific
subject groups. A P < 0.05 was considered statistically sig-
nificant.
Results
To examine the association of SLC2A10 variants with
T2DM, 20 SNPs spanning the genomic region were evalu-
ated. The average SNP density was 1 SNP/5.2 kb with
inter-SNP distances ranging from 0.078 kb to 26.856 kb.
The location of the SNPs relative to the exon-intron struc-
ture of SLC2A10 is shown in Figure 1. The 20 SNPs were
genotyped in a collection of Caucasian T2DM-ESRD cases
(n = 300) and controls (n = 310) and single SNP associa-
tion analysis was performed on those SNPs with minor
allele frequencies greater than 0.20. Five of the SNPs are
located in coding regions (rs6094438, rs2235491,
rs6018008, rs707507, rs1059217), but only rs1059217
had a minor allele frequency greater than 0.20. The coding
variant rs2235491 (Ala206Thr) had a low minor allele fre-
quency of 0.04, but was included since it has been previ-
ously described as associated with reduced fasting insulin
[18]. The remaining coding variants, rs6094438,
rs6018008, rs707507, are so rare that they are very poorly
informative with minor allele frequencies ≤ 0.01. In addi-
tion two SNPs in the noncoding regions, rs4428069 and
rs609440, were also found to be nonpolymorphic.
In the control population, rs2076293 (P = <0.0001) and
rs6090547 (P = 0.00043) did not conform to Hardy-
Weinberg equilibrium. The allelic association analysis is
summarized in Table 1, which shows the SNP identifier,
the relevant alleles for each SNP, frequencies in cases and
Table 1: Association analysis for SLC2A10 SNPs in Caucasian T2DM-ESRD cases and controls.
Genotype 
Frequency: Cases
Genotype Frequency: 
Ccontrols
SNP Alleles 1/1 1/2 2/2 Frequency in 
Cases (n = 300)
1/1 1/2 2/2 Frequency in 
Controls (n = 310)
P-value
rs1004571 A/G 25 125 146 0.30/0.70 28 139 141 0.32/0.68 0.426
rs6012006 A/C 26 104 159 0.27/0.73 29 130 135 0.32/0.68 0.063
rs4810542 G/A 3 40 246 0.08/0.92 0 33 271 0.05/0.95 0.094
rs4810544 C/T 4 33 257 0.07/0.93 0 33 277 0.05/0.95 0.263
rs2425897 A/T 0 17 279 0.03/0.97 0 19 287 0.03/0.97 0.78
rs2425902 G/A 25 119 151 0.29/0.71 37 120 146 0.32/0.68 0.207
rs2235491 A/G 4 16 276 0.04/0.96 1 16 288 0.03/0.97 0.37
*rs2076293 A/G 12 229 56 0.43/0.57 2 213 65 0.39/0.61 0.025
rs2425906 G/T 47 138 113 0.39/0.61 57 139 112 0.41/0.59 0.484
rs2425907 T/C 45 140 113 0.39/0.61 56 140 112 0.41/0.59 0.401
rs998422 G/A 46 139 114 0.39/0.61 58 138 108 0.42/0.58 0.289
rs2425911 G/C 26 123 146 0.30/0.70 40 121 144 0.33/0.67 0.213
rs3091904 C/T 44 147 107 0.39/0.61 59 139 111 0.42/0.58 0.541
rs1059217 C/T 46 137 104 0.40/0.60 60 137 111 0.42/0.58 0.567
*rs6090547 C/T 71 108 90 0.47/0.53 67 107 102 0.44/0.56 0.381
*Variant not consistent with Hardy-Weinberg proportions
P-values in bold indicates P ≤ 0.05BMC Medical Genetics 2005, 6:42 http://www.biomedcentral.com/1471-2350/6/42
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controls, and P-values. This analysis revealed moderate
evidence of association between SNP rs2076293 and
T2DM (P = 0.025). In addition, genotypic association
analysis showed moderate evidence of association of this
variant with T2DM under an additive model (P = 0.039).
However, these results should be viewed with caution
since the proportions of the genotypes for the variant are
significantly out of Hardy-Weinberg equilibrium in the
control population.
Linkage disequilibrium (LD) and haplotype structure of
SLC2A10 were determined to assess whether any specific
haplotypes were associated with T2DM. Inter-SNP D' sta-
tistics were calculated for the gene region as shown in Fig-
ure 2 using LD Viewer (unpublished). The upper portion
of the matrix displays the calculated inter-SNP D' values,
where a D' ≥ 0.70 is defined as high LD. The lower portion
of the matrix shows the calculated P-values for each D'
value, where a P-value ≤ 0.05 is significant (e.g. the calcu-
lated D' value is significant). Using these criteria (D' ≥
0.70, P ≤ 0.05), SLC2A10 SNPs appear to be one LD block
covering a 14 kb region which begins with variant
rs2425902 in intron 1 and ends beyond the 3'-UTR with
variant rs1059217.
Haplotype frequencies were estimated and association
analyses performed using the programs Dandelion [22]
and HAPLO.SCORE [21]. Shown in Table 2 are the results
from the analyses evaluating 7 SNP haplotypes within the
single major LD block of the SLC2A10 gene. Three com-
mon haplotypes are estimated and no significant evidence
of haplotype association was observed with T2DM. It is
important to note that although the variants rs2235491
and rs2235491 were within the LD block, they were
Marker-to-marker D' plot for the SLC2A10 SNPs Figure 2
Marker-to-marker D' plot for the SLC2A10 SNPs. Inter-SNP D' values are graphically represented using LD Viewer which gen-
erates a color coded plot of the pair-wise statistics in the upper portion of the matrix, and a color coded plot of the calculated 
P-value for each LD measurement in the bottom portion of the matrix.BMC Medical Genetics 2005, 6:42 http://www.biomedcentral.com/1471-2350/6/42
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removed from the analysis due to their low minor allele
frequencies (rs2235491) or due to departure from Hardy-
Weinberg equilibrium (rs2235491).
Discussion
SNPs spanning the SLC2A10 genomic sequence have
been genotyped in a Caucasian American T2DM case-con-
trol population. Most of the coding SNPs validated in this
gene region were so rare in this study sample that they
were uninformative for our analysis. The remaining SNPs
did not show significant evidence for association to
T2DM. This included SNP rs2235491 (Ala206Thr) which
was previously reported to be associated with fasting insu-
lin (but without evidence of associaton with T2DM) [18].
Linkage disequilibrium analysis suggests that there is one
LD block covering a 14 kb region beginning with variant
rs2425902 in intron 1 and ending with variant rs1059217
in the 3'UTR region. Haplotype analysis based on the LD
structure did not reveal evidence for association with
T2DM. However, the study is not powered (with the crite-
rion MAF > 0.1) or designed to address less common SNPs
or haplotypes. We have carried out a detailed power anal-
ysis for this case-control study group elsewhere (Bento et
al, submitted). Briefly, assuming a T2DM disease preva-
lence of 10% and modest multiplicative genotype risk
ratios of 1.5, the power to detect association at a nominal
SNP significance level of 5% is 74.7% under an additive
trend test with risk allele frequency of 10%, and >95% for
risk allele frequency 20%.
Conclusion
From these observations, we can conclude that variants in
or near GLUT10 do not contribute substantially to T2DM
in this sample of Caucasian Americans. This does not
exclude the possibility that evidence for association could
be observed in a larger case-control study or a study with
cases ascertained in a different manner. However, another
study has confirmed these negative association results.
When examining SNPs in SLC2A10 using a Finnish popu-
lation, no significant evidence for T2DM association with
any SNP was observed [23]. In addition, this same study
and another performed in a Danish population could not
confirm the published association of Ala206Thr and fast-
ing insulin [18, 24]. It is noteworthy that we have
observed evidence for association to T2DM with the
nearby PTPN1 gene, and to a lesser extent, with the
HNF4A gene which is also located within 20q12-13.1.
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